Safety and Efficacy of Drug Combinations Against Schistosomiasis

Gaps in Helminth Control: Safety and Efficacy of Drug Combinations. Praziquantel Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01050374

Enrollment

650

Registered

2010-01-15

Start date

2007-10-31

Completion date

2008-10-31

Last updated

2010-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parasitic Diseases

Brief summary

This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of MBD in combination with PZQ in the treatment of SCH and STH in children aged 1-15 years of age.

Interventions

DRUGalbendazole + praziquantel

albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)

DRUGmebendazole + praziquantel

mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

1 Years to 15 Years

Healthy volunteers

Inclusion criteria

* Those with an age of 1-15 years of age * Are infected with schistosomiasis and soil-transmitted helminthiasis * Whose parent consent and who are willing to participate

Exclusion criteria

* Those with acute and chronic diseases other than schistosomiasis and soil-transmitted helminthiasis * Those with a history of any serious adverse drug reactions

Design outcomes

Primary

Measure	Time frame
Efficacy of treatment	6 weeks

Secondary

Measure	Time frame
Record of adverse reactions	6 weeks

Countries

Uganda

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026